These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys
Three healthcare dividend stocks—AbbVie, Gilead Sciences, and Becton, Dickinson—have significantly outperformed the S&P 500 in 2026, with gains of 29%, 37%, and 43% respectively. All three are recommended as continued buys due to strong underlying businesses, solid dividend programs (two are Dividend Kings), and favorable long-term growth prospects driven by key product pipelines and market tailwinds.
